Logo image of OMER

OMEROS CORP (OMER) Stock Price, Quote, News and Overview

NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock - Currency: USD

9.18  -0.43 (-4.47%)

After market: 9.18 0 (0%)

OMER Quote, Performance and Key Statistics

OMEROS CORP

NASDAQ:OMER (2/21/2025, 8:00:01 PM)

After market: 9.18 0 (0%)

9.18

-0.43 (-4.47%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High13.6
52 Week Low2.61
Market Cap531.98M
Shares57.95M
Float55.37M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)02-26 2025-02-26/amc
IPO10-08 2009-10-08


OMER short term performance overview.The bars show the price performance of OMER in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

OMER long term performance overview.The bars show the price performance of OMER in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100

The current stock price of OMER is 9.18 USD. In the past month the price increased by 1.89%. In the past year, price increased by 122.82%.

OMEROS CORP / OMER Daily stock chart

OMER Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.44 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.58 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.78 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About OMER

Company Profile

OMER logo image Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 198 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Company Info

OMEROS CORP

201 Elliott Avenue West

Seattle WASHINGTON 98119 US

CEO: Gregory A. Demopulos

Employees: 198

Company Website: https://www.omeros.com/

Investor Relations: https://investor.omeros.com/

Phone: 12066765000

OMEROS CORP / OMER FAQ

What is the stock price of OMEROS CORP today?

The current stock price of OMER is 9.18 USD. The price decreased by -4.47% in the last trading session.


What is the ticker symbol for OMEROS CORP stock?

The exchange symbol of OMEROS CORP is OMER and it is listed on the Nasdaq exchange.


On which exchange is OMER stock listed?

OMER stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for OMEROS CORP stock?

10 analysts have analysed OMER and the average price target is 40.29 USD. This implies a price increase of 338.89% is expected in the next year compared to the current price of 9.18. Check the OMEROS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OMEROS CORP worth?

OMEROS CORP (OMER) has a market capitalization of 531.98M USD. This makes OMER a Small Cap stock.


How many employees does OMEROS CORP have?

OMEROS CORP (OMER) currently has 198 employees.


What are the support and resistance levels for OMEROS CORP (OMER) stock?

OMEROS CORP (OMER) has a support level at 9.02 and a resistance level at 9.62. Check the full technical report for a detailed analysis of OMER support and resistance levels.


Should I buy OMEROS CORP (OMER) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OMEROS CORP (OMER) stock pay dividends?

OMER does not pay a dividend.


When does OMEROS CORP (OMER) report earnings?

OMEROS CORP (OMER) will report earnings on 2025-02-26, after the market close.


What is the Price/Earnings (PE) ratio of OMEROS CORP (OMER)?

OMEROS CORP (OMER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.31).


What is the Short Interest ratio of OMEROS CORP (OMER) stock?

The outstanding short interest for OMEROS CORP (OMER) is 16.91% of its float. Check the ownership tab for more information on the OMER short interest.


OMER Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to OMER. When comparing the yearly performance of all stocks, OMER is one of the better performing stocks in the market, outperforming 94.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

OMER Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to OMER. OMER may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OMER Financial Highlights

Over the last trailing twelve months OMER reported a non-GAAP Earnings per Share(EPS) of -2.31. The EPS decreased by -821.88% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -42.93%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%6.67%
Sales Q2Q%N/A
EPS 1Y (TTM)-821.88%
Revenue 1Y (TTM)N/A

OMER Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to OMER. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners46.12%
Ins Owners4.42%
Short Float %16.91%
Short Ratio12.42
Analysts
Analysts80
Price Target40.29 (338.89%)
EPS Next Y-53%
Revenue Next YearN/A